[A22-33] Vedolizumab (antibiotic refractory chronic pouchitis) – Benefit assessment according to §35a Social Code Book V

Last updated 01.06.2022

Project no.:
A22-33

Commission:
Commission awarded on 28.03.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Immune system and infections

Indication:

Adults with moderately to severely active chronic pouchitis, who have had an inadequate response with or lost response to antibiotic therapy or have had intolerance to this treatment, and who had undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.